Third quarter 2024 results
Third quarter 2024 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.
Friday October 25, 2024
14:00 - 15:30 CET (8:00am – 9:30am EST)
Featuring
Paul Hudson
Chief Executive Officer
François Roger
Chief Financial Officer
Houman Ashrafian
Head of Research and Development
Highlights
Our strong performance continues in Q3, boosted by sales of flu and RSV vaccines, the steady progress of our new pharma launches, and the continued momentum of our best-in-class biologic, now approved in six type 2 inflammatory diseases and treating more than 1 million patients worldwide.
Paul Hudson
Chief Executive Officer